These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33573814)

  • 21. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
    Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
    Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.
    Urban M; Slavcev A; Gazdic T; Ivak P; Besik J; Netuka I
    Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):292-7. PubMed ID: 26675563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
    Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
    Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody.
    In JW; Park H; Rho EY; Shin S; Park KU; Park MH; Song EY
    Transplant Proc; 2014 Dec; 46(10):3371-4. PubMed ID: 25498054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.
    Lee J; Huh KH; Park Y; Park BG; Yang J; Jeong JC; Lee J; Park JB; Cho JH; Lee S; Ro H; Han SY; Kim MS; Kim YS; Kim SJ; Kim CD; Chung W; Park SB; Ahn C;
    Nephrol Dial Transplant; 2017 Jul; 32(7):1244-1250. PubMed ID: 26546592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Treatment of Anti-angiotensin II Type 1 Receptor Antibody-Associated Rejection in Kidney Transplantation: A Case Report.
    Wiwattanathum P; Ingsathit A; Thammanichanond D; Worawichawong S
    Transplant Proc; 2018 Apr; 50(3):877-880. PubMed ID: 29331505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of AT1R antibody (AT1R-Ab) among Malaysian multi-ethnic population.
    Jalalonmuhali M; Caroll R; Deayton S; Emery T; Humphreys I; Lim SJ; Lim SK; Coates T
    Hum Immunol; 2020 Dec; 81(12):679-684. PubMed ID: 32736900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-transplant angiotensin II receptor type I antibodies in pediatric renal transplant recipients: An observational cohort study.
    Pizzo H; Mirocha J; Choi J; Garrison J; Haas M; Zhang X; Kamil ES; Kim I; Jordan SC; Puliyanda DP
    Pediatr Transplant; 2022 Dec; 26(8):e14400. PubMed ID: 36168673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients.
    Sorohan BM; Ismail G; Berechet A; Obrișcă B; Constantinescu I; Mărunțelu I; Tacu D; Baston C; Sinescu I
    Transpl Immunol; 2021 Jun; 66():101389. PubMed ID: 33838295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-Transplant Angiotensin II Type 1 Receptor Antibodies and Anti-Endothelial Cell Antibodies Predict Graft Function and Allograft Rejection in a Low-Risk Kidney Transplantation Setting.
    Yu S; Huh HJ; Lee KW; Park JB; Kim SJ; Huh W; Jang HR; Kwon GY; Moon HH; Kang ES
    Ann Lab Med; 2020 Sep; 40(5):398-408. PubMed ID: 32311853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
    Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens.
    Delville M; Lamarthée B; Pagie S; See SB; Rabant M; Burger C; Gatault P; Giral M; Thaunat O; Arzouk N; Hertig A; Hazzan M; Matignon M; Mariat C; Caillard S; Kamar N; Sayegh J; Westeel PF; Garrouste C; Ladrière M; Vuiblet V; Rivalan J; Merville P; Bertrand D; Le Moine A; Duong Van Huyen JP; Cesbron A; Cagnard N; Alibeu O; Satchell SC; Legendre C; Zorn E; Taupin JL; Charreau B; Anglicheau D
    J Am Soc Nephrol; 2019 Apr; 30(4):692-709. PubMed ID: 30850439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome.
    Pinelli DF; Friedewald JJ; Haarberg KMK; Radhakrishnan SL; Zitzner JR; Hanshew WE; Tambur AR
    Hum Immunol; 2017; 78(5-6):421-427. PubMed ID: 28372986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early critical cortical infarction by anti-angiotensin II type 1 receptor antibody: A case report and literature review.
    Lim JH; Han MH; Kim YJ; Huh S; Kim CD
    Medicine (Baltimore); 2021 May; 100(21):e25958. PubMed ID: 34032705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
    Okada M; Tomosugi T; Futamura K; Hiramitsu T; Goto N; Narumi S; Takeda A; Watarai Y
    Transplant Proc; 2020 Dec; 52(10):3051-3057. PubMed ID: 32694058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-HLA Antibodies to G Protein-coupled Receptors in Pediatric Kidney Transplant Recipients: Short- and Long-term Clinical Outcomes.
    Pearl MH; Chen L; Zuckerman JE; Weng PL; Chambers ET; Zhang Q; Reed EF
    Transplantation; 2024 Jan; 108(1):276-283. PubMed ID: 37527494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome.
    Reinsmoen NL; Mirocha J; Ensor CR; Marrari M; Chaux G; Levine DJ; Zhang X; Zeevi A
    Transplantation; 2017 Jun; 101(6):1215-1221. PubMed ID: 27973391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.